Your sarcasm aside, thank you for the information. (BTW, I do not own MBOT but I do follow it.) Even if the Australian government provides several million dollars in clinical trial reimbursement, I still don't see how the numbers add up. Right now, Anavex is spending about $1MM+ a month without any trials other than the extension study. They said current cash is sufficient for two years. The 2b/3 trials in Australia and N. America, and the US Rett study and Spain PD study will require force significant additional spending over the next 12 months (another million a month doesn't seem an unreasonable guesstimate for global clinical trials). If that $1MM is in the ballpark, Anavex would go below one year of cash before the end of 2019, which would be a red flag. The Cantor ATM is available but tapping $10+ million inside of a year to fund clinical trials doesn't seem feasible. Even if sufficient funds can be raised through Cantor, massive dilution is inevitable.
Market Data 
Markets 
AI
